Notification
No new Notification messages
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Diwali Offer: MTF at just 9.99%
Iss Diwali, Investments Ko Karo 4X with our Trade Now, Pay Later (MTF) feature
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
cipla ltd stock

CIPLA LTD Share Price

1560 8.25 (0.53%)
Nov 01 2024 06:59 PM Pharmaceuticals NSE: CIPLA

CIPLA LTD Share Price Update

As of the latest trading session, CIPLA LTD share price is currently at 1560, which is up by 8.25 from its previous closing. Today, the stock has fluctuated between 1551.75 and 1573.45. Over the past year, CIPLA LTD has achieved a return of 29.31 %. In the last month alone, the return has been -6.18 %. Read More...

CIPLA LTD Performance

Day Range

Low1551.75 High1573.45
1551.75

52 Week Range

Low 1164.55 High 1702.05
1551.75

CIPLA LTD Share Price

694

500087

CIPLA

img img img img
No Data Available

Open Price

1565.10

Prev. Close

1551.75

Volume (Shares)

17447689.00

Total traded value

270744.51

Upper Circuit

1706.90

Lower Circuit

1396.60

Note: The current prices & values are delayed, Login to your account for live updates.

CIPLA LTD Fundamentals


(Standalone)

Market Cap (Cr) 125949.30
PE Ratio (TTM) 28.59
Book Value / Share 360.74
Beta 0.22
ROE 15.50%
EPS (TTM) 52.43
Dividend Yield 0.84%
Net Profit Qtr (Cr) 1178.16

CIPLA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 3969.86
Operating Expense 3485.70
Net Profit 1178.16
Net Profit Margin (%) 29.67
Earnings Per Share (EPS) 14.59
EBITDA 1727.18
Effective Tax Rate (%) 25.36
Particulars JUN 2024 (Values in Cr)
Revenue 3752.25
Operating Expense 3284.12
Net Profit 1055.94
Net Profit Margin (%) 28.14
Earnings Per Share (EPS) 13.08
EBITDA 1573.38
Effective Tax Rate (%) 26.18
Particulars MAR 2024 (Values in Cr)
Revenue 3444.92
Operating Expense 3351.02
Net Profit 1038.40
Net Profit Margin (%) 30.14
Earnings Per Share (EPS) 12.86
EBITDA 1366.50
Effective Tax Rate (%) 19.78
Particulars DEC 2023 (Values in Cr)
Revenue 3798.31
Operating Expense 3169.54
Net Profit 1114.14
Net Profit Margin (%) 29.33
Earnings Per Share (EPS) 14.99
EBITDA 1524.84
Effective Tax Rate (%) 26.28
Particulars SEP 2023 (Values in Cr)
Revenue 3736.46
Operating Expense 3195.48
Net Profit 1029.69
Net Profit Margin (%) 27.55
Earnings Per Share (EPS) 14.17
EBITDA 1430.46
Effective Tax Rate (%) 26.40
Particulars MAR 2024 (Values in Cr)
Revenue 14441.14
Operating Expense 12698.03
Net Profit 4077.25
Net Profit Margin (%) 28.23
Earnings Per Share (EPS) 50.51
EBITDA 5554.81
Effective Tax Rate (%) 24.91
Particulars MAR 2023 (Values in Cr)
Revenue 13073.53
Operating Expense 11610.63
Net Profit 2513.47
Net Profit Margin (%) 19.22
Earnings Per Share (EPS) 31.15
EBITDA 3623.77
Effective Tax Rate (%) 28.66
Particulars MAR 2022 (Values in Cr)
Revenue 15052.48
Operating Expense 12243.14
Net Profit 2957.93
Net Profit Margin (%) 19.65
Earnings Per Share (EPS) 36.67
EBITDA 4377.93
Effective Tax Rate (%) 24.22
Particulars MAR 2021 (Values in Cr)
Revenue 11060.17
Operating Expense 8748.99
Net Profit 2468.28
Net Profit Margin (%) 22.31
Earnings Per Share (EPS) 30.61
EBITDA 3297.69
Effective Tax Rate (%) 26.55
Particulars MAR 2020 (Values in Cr)
Revenue 12220.22
Operating Expense 10587.68
Net Profit 2318.17
Net Profit Margin (%) 18.96
Earnings Per Share (EPS) 28.76
EBITDA 3600.14
Effective Tax Rate (%) 21.79
Particulars MAR 2024 (Values in Cr)
Book Value / Share 330.79
ROE % 16.58
ROCE % 22.27
Total Debt to Total Equity 0.03
EBITDA Margin 26.55
Particulars MAR 2023 (Values in Cr)
Book Value / Share 290.01
ROE % 12.82
ROCE % 17.79
Total Debt to Total Equity 0.04
EBITDA Margin 23.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 258.33
ROE % 13.07
ROCE % 16.83
Total Debt to Total Equity 0.08
EBITDA Margin 21.37
Particulars MAR 2021 (Values in Cr)
Book Value / Share 227.25
ROE % 14.09
ROCE % 17.39
Total Debt to Total Equity 0.14
EBITDA Margin 23.58
Particulars MAR 2020 (Values in Cr)
Book Value / Share 195.51
ROE % 10.05
ROCE % 12.19
Total Debt to Total Equity 0.23
EBITDA Margin 20.72
Particulars MAR 2024 (Values in Cr)
Book Value / Share 346.49
ROE % 15.50
ROCE % 20.10
Total Debt to Total Equity 0.00
EBITDA Margin 35.71
Particulars MAR 2023 (Values in Cr)
Book Value / Share 305.25
ROE % 10.66
ROCE % 14.28
Total Debt to Total Equity 0.00
EBITDA Margin 27.84
Particulars MAR 2022 (Values in Cr)
Book Value / Share 279.05
ROE % 13.94
ROCE % 18.21
Total Debt to Total Equity 0.00
EBITDA Margin 28.95
Particulars MAR 2021 (Values in Cr)
Book Value / Share 247.10
ROE % 13.22
ROCE % 17.18
Total Debt to Total Equity 0.00
EBITDA Margin 32.92
Particulars MAR 2020 (Values in Cr)
Book Value / Share 215.85
ROE % 13.97
ROCE % 17.81
Total Debt to Total Equity 0.00
EBITDA Margin 28.44
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 874.97
Total Assets 32717.82
Total Liabilities 32717.82
Total Equity 26802.33
Share Outstanding 807367062
Price to Book Ratio 4.31
Return on Assets (%) 12.59
Return on Capital (%) 15.24
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1564.62
Total Assets 29463.28
Total Liabilities 29463.28
Total Equity 23713.54
Share Outstanding 807150593
Price to Book Ratio 2.95
Return on Assets (%) 9.50
Return on Capital (%) 11.56
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1928.48
Total Assets 27101.12
Total Liabilities 27101.12
Total Equity 21117.38
Share Outstanding 806814036
Price to Book Ratio 3.65
Return on Assets (%) 9.28
Return on Capital (%) 11.47
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1401.23
Total Assets 25151.89
Total Liabilities 25151.89
Total Equity 18585.59
Share Outstanding 806463279
Price to Book Ratio 3.30
Return on Assets (%) 9.56
Return on Capital (%) 11.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1003.91
Total Assets 23662.56
Total Liabilities 23662.56
Total Equity 16057.28
Share Outstanding 806235329
Price to Book Ratio 1.96
Return on Assets (%) 6.53
Return on Capital (%) 8.19
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 333.20
Total Assets 31053.23
Total Liabilities 31053.23
Total Equity 27973.92
Share Outstanding 807367062
Price to Book Ratio 4.31
Return on Assets (%) 13.12
Return on Capital (%) 14.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 966.46
Total Assets 27596.47
Total Liabilities 27596.47
Total Equity 24638.09
Share Outstanding 807150593
Price to Book Ratio 2.95
Return on Assets (%) 9.10
Return on Capital (%) 10.2
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1428.03
Total Assets 25449.05
Total Liabilities 25449.05
Total Equity 22513.55
Share Outstanding 806814036
Price to Book Ratio 3.65
Return on Assets (%) 11.62
Return on Capital (%) 13.14
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 874.80
Total Assets 22963.74
Total Liabilities 22963.74
Total Equity 19927.56
Share Outstanding 806463279
Price to Book Ratio 3.30
Return on Assets (%) 10.74
Return on Capital (%) 12.39
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 523.07
Total Assets 20405.66
Total Liabilities 20405.66
Total Equity 17402.96
Share Outstanding 806235329
Price to Book Ratio 1.96
Return on Assets (%) 11.36
Return on Capital (%) 13.32
Particulars MAR 2024 (Values in Cr)
Net Income 5896.72
Cash from Operations 5731.39
Cash from Investing -2988.03
Cash from Financing -1200.43
Net change in Cash -54.55
Free Cash Flow 6829.64
Particulars MAR 2023 (Values in Cr)
Net Income 4220.77
Cash from Operations 4539.54
Cash from Investing -2388.51
Cash from Financing -958.29
Net change in Cash -109.15
Free Cash Flow 5380.07
Particulars MAR 2022 (Values in Cr)
Net Income 3675.39
Cash from Operations 4465.40
Cash from Investing -1871.88
Cash from Financing -1599.79
Net change in Cash -145.77
Free Cash Flow 5009.50
Particulars MAR 2021 (Values in Cr)
Net Income 3290.06
Cash from Operations 4792.63
Cash from Investing -2387.18
Cash from Financing -1239.51
Net change in Cash 128.51
Free Cash Flow 5422.29
Particulars MAR 2020 (Values in Cr)
Net Income 2178.18
Cash from Operations 3916.70
Cash from Investing 104.04
Cash from Financing -2948.82
Net change in Cash 223.67
Free Cash Flow 4489.46
Particulars MAR 2024 (Values in Cr)
Net Income 5432.14
Cash from Operations 4950.93
Cash from Investing -2882.82
Cash from Financing -708.83
Net change in Cash 135.12
Free Cash Flow 5501.42
Particulars MAR 2023 (Values in Cr)
Net Income 3685.17
Cash from Operations 4119.31
Cash from Investing -2757.95
Cash from Financing -424.77
Net change in Cash -147.67
Free Cash Flow 4705.71
Particulars MAR 2022 (Values in Cr)
Net Income 3905.08
Cash from Operations 3707.46
Cash from Investing -2463.73
Cash from Financing -426.72
Net change in Cash -117.02
Free Cash Flow 4012.50
Particulars MAR 2021 (Values in Cr)
Net Income 3350.66
Cash from Operations 4412.26
Cash from Investing -3360.45
Cash from Financing -65.80
Net change in Cash 34.06
Free Cash Flow 4929.23
Particulars MAR 2020 (Values in Cr)
Net Income 2964.31
Cash from Operations 2683.12
Cash from Investing -1126.33
Cash from Financing -693.89
Net change in Cash 197.92
Free Cash Flow 3132.83
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 54.46 35.36 3.04 417.34 35.27 / 77.70
BLISS GVS PHARMA LTD 123.40 15.44 1.28 1299.43 83.85 / 148.95
FERMENTA BIOTECH LIMITED 302.75 0.00 3.08 891.02 144.45 / 332.50
GLAXOSMITHKLINE PHARMA LT 2719.80 57.46 27.54 46075.05 1387.90 / 3087.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 54.46 82.52 10.35 417.34 35.27 / 77.70
AMRUTAJAN HEALTH LTD 760.30 51.62 7.61 2198.08 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 7606.70 145.17 26.71 19016.75 4050.15 / 8139.85
BLISS GVS PHARMA LTD 123.40 16.07 1.26 1299.43 83.85 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1494.20
  • 26 Days 1554.50
  • 10 Days 1503.40
  • 50 Days 1580.00
  • 12 Days 1509.00
  • 100 Days 1565.20
  • 20 Days 1542.30
  • 200 Days 1357.40
1420.42
PIVOT
First Resistance 1437.83
Second Resistance 1457.42
Third Resistance 1474.83
First Support 1400.83
Second Support 1383.42
Third Support 1363.83
RSI 43.86
MACD -45.46
Commodity Channel Index (CCI) -12.84
ADX 45.10
Williams % R -26.71

Over 1 Month

down

-6.18

Over 3 Months

down

0.48

Over 6 Months

down

10.83

Over 1 Year

down

29.31

Over 3 Years

down

19.50

Over 5 Years

down

27.15

CIPLA LTD Future

Future: Price

28 Nov
1566.00
26 Dec
1573.10
25 May
0 100 200 300 400 500 600

Discount/Premium

28 Nov
14.25
26 Dec
21.35
25 May
0 1 2 3 4 5 6 7

Active Calls

1600.0
17191
1560.0
9941
1540.0
9274
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1500.0
8551
1400.0
5642
1540.0
4798
25 Jul
0 500 1000 1500 2000 2500

CIPLA LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
22.8
Promoter Holdings
30.92
FII
28.79
DII
17.47
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Yusuf Khwaja Hameid Shareholding of Promoter and Promoter Group 1.50521183E8 18.68
Sophie Ahmed Shareholding of Promoter and Promoter Group 4.5982E7 5.71
Hdfc Mutual Fund-hdfc Arbitrage Fund Public Shareholding 4.1176157E7 5.11
M K Hamied Shareholding of Promoter and Promoter Group 2.784432E7 3.46
Lici Money Plus Balanced Fund Public Shareholding 2.5190429E7 3.13
Sbi Arbitrage Opportunities Fund Public Shareholding 2.2122027E7 2.75
Government Pension Fund Global Public Shareholding 1.700486E7 2.11
Nps Trust Public Shareholding 1.1343347E7 1.41
Kamil Hamied Shareholding of Promoter and Promoter Group 1.09395E7 1.36
Samina Hamied Shareholding of Promoter and Promoter Group 8954750.0 1.11
Icici Prudential Equity Arbitrage Fund Public Shareholding 8938390.0 1.11
Uti Nifty 50 Index Fund Public Shareholding 8405817.0 1.04
Kotak Equity Hybrid Public Shareholding 8301172.0 1.03
Rumana Hamied Shareholding of Promoter and Promoter Group 4943250.0 0.61
Farida Hamied Shareholding of Promoter and Promoter Group 0.0 0.0
Okasa Pharma Private Limited Shareholding of Promoter and Promoter Group 0.0 0.0
Hamsons Laboratories Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Alps Remedies Private Limited Shareholding of Promoter and Promoter Group 0.0 0.0
Shree Riddhi Chemicals Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Mn Rajkumar Garments Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Shirin Hamied Shareholding of Promoter and Promoter Group 0.0 0.0

CIPLA LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2024-08-02 13.0 Final 2024-08-02 Equity shares 2023-07-21 8.5 Final 2023-07-21 Equity shares 2022-08-08 5.0 Final 2022-08-10 Equity shares 2021-08-09 5.0 Final 2021-08-11 Equity shares 2020-03-19 3.0 Interim 2020-03-20 Equity shares 2020-03-19 1.0 Special 2020-03-20 Equity shares 2019-07-31 3.0 Final 2019-08-02 Equity shares 2018-08-13 3.0 Final 2018-08-16 Equity shares 2017-07-26 2.0 Final 2017-07-28 Equity shares 2016-09-12 2.0 Final 2016-09-15 Equity shares 2015-08-11 2.0 Final 2015-08-13 Equity shares 2014-08-06 2.0 Final 2014-08-08 Equity shares 2013-08-06 2.0 Final 2013-08-08 Equity shares 2012-08-01 2.0 Final 2012-08-03 Equity shares 2011-08-09 2.0 Final 2011-08-11 Equity shares 2010-09-03 0.8 Interim 2010-09-06 Equity shares 2010-07-23 2.0 Final 2010-07-27 Equity shares 2009-08-10 2.0 Final 2009-08-12 Equity shares 2008-08-12 2.0 Final 2008-08-14 Equity shares 2007-08-08 2.0 Final 2007-08-10 Equity shares 2006-08-18 0.0 Final 2006-08-22 Equity shares 2005-08-19 0.0 Final 2005-08-23 Equity shares
Ex-Date Ex-Bonus Ratio
2006-04-25 2006-04-24 3:2 1999-11-05 1999-10-18 2:1
Ex-Date Old FV NEW FV Record Date
2004-05-11 10.0 2.0 2004-05-19

Cipla Limited Overview

Cipla, established in 1990, is a leading pharmaceutical entity in India, holding significant market positions in therapies like respiratory and urology, and a broad product portfolio of over 1,500 products across 65 therapeutic categories. With a strong footprint in India and a significant presence in emerging markets, Cipla has become the 3rd largest pharmaceutical company in India and a major exporter. The company's expertise in manufacturing generic APIs, with over 200 generics supplied to 62 countries, underlines its role as a preferred partner globally. Cipla's manufacturing prowess is supported by 47 state-of-the-art facilities across six countries, enabling a diversified product range from antidepressants to antivirals. Strategic partnerships for COVID-19 treatments with major pharmaceutical companies, acquisitions to bolster renewable energy initiatives, and a joint venture for biologic product development illustrate Cipla's forward-looking approach. With subsidiaries streamlined for operational efficiency and a scheme of arrangement to optimise its business structure, Cipla invests heavily in R&D, underscoring its commitment to innovation. As it aims to expand its lung specialty offerings, Cipla continues to deepen its focus on antidiabetics and oncology, aiming to partner with global corporations to enhance its market reach and therapeutic impact.

Learn More About Stocks

About CIPLA LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by CIPLA LTD

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Cipla Ltd?

Answer Field

The share price of Cipla Ltd for NSE is ₹ 1560 and for BSE is ₹ 1560.7.

What is the Market Cap of Cipla Ltd?

Answer Field

The market cap of Cipla Ltd for NSE is ₹ 12,59,49.30 Cr. and for BSE is ₹ 12,60,05.80 Cr. as of now.

What is the 52 Week High and Low of Cipla Ltd?

Answer Field

The 52 Week High and Low of Cipla Ltd for NSE is ₹ 1702.05 and ₹ 1164.55 and for BSE is ₹ 1702.00 and ₹ 1165.10.

How to Buy Cipla Ltd share?

Answer Field

You can trade in Cipla Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Cipla Ltd?

Answer Field

The 1 year returns on the stock has been 29.31%.

What is the Current Share Price of Cipla Ltd?

Answer Field

Cipla Ltd share price is for NSE ₹ 1560 & for BSE ₹ 1560.7 as on Nov 01 2024 06:59 PM.

What is the Market Cap of Cipla Ltd Share?

Answer Field

The market cap of Cipla Ltd for NSE ₹ 12,59,49.30 & for BSE ₹ 12,60,05.80 as on Nov 01 2024 06:59 PM.

What is the P/E Ratio of Cipla Ltd Share?

Answer Field

As on Nov 01 2024 06:59 PM the price-to-earnings (PE) ratio for Cipla Ltd share is 28.59.

What is the PB ratio of Cipla Ltd Share?

Answer Field

As on Nov 01 2024 06:59 PM, the price-to-book (PB) ratio for Cipla Ltd share is 360.74.

How to Buy Cipla Ltd Share?

Answer Field

You can trade in Cipla Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Cipla Ltd Share on Bajaj Broking App?

Answer Field

To buy Cipla Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Cipla Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader